Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report

Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illu...

Descripción completa

Detalles Bibliográficos
Autores principales: Witting, Celeste, Quaggin-Smith, Jessica, Mylvaganam, Ruben, Peigh, Graham, Angarone, Michael, Flaherty, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677089/
https://www.ncbi.nlm.nih.gov/pubmed/33388572
http://dx.doi.org/10.1016/j.diagmicrobio.2020.115272
Descripción
Sumario:Tocilizumab, an interleukin-6 receptor antagonist, has been used to treat critically ill patients with coronavirus disease-2019. We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy.

Ejemplares similares